Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

4.10
-0.0700-1.68%
Post-market: 4.100.00000.00%18:40 EDT
Volume:603.50K
Turnover:2.45M
Market Cap:316.17M
PE:-4.13
High:4.12
Open:4.10
Low:3.96
Close:4.17
Loading ...

Corvus Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
01 Aug

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

GlobeNewswire
·
01 Aug

Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says

MT Newswires Live
·
08 Jul

Director and 10% Owner Peter A. Thompson Reports Disposal of Common Shares of Corvus Pharmaceuticals Inc

Reuters
·
02 Jul

Corvus Pharmaceuticals Gets China Nod to Begin Atopic Dermatitis Drug Trial

MT Newswires Live
·
25 Jun

BRIEF-Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For A Phase 1B/2 Clinical Trial Of Soquelitinib

Reuters
·
25 Jun

Mizuho Securities Remains a Buy on Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
25 Jun

Corvus Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
14 Jun

Cantor Fitzgerald Remains a Buy on Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
12 Jun

Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis

Reuters
·
04 Jun

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating

MT Newswires Live
·
20 May

Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings

TIPRANKS
·
10 May

Corvus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
10 May

Corvus Pharmaceuticals Price Target Raised to $17.00/Share From $15.00 by Oppenheimer

Dow Jones
·
10 May

Corvus Pharmaceuticals Up Over 26%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk

Dow Jones
·
09 May

Wall Street Set to Open Higher Friday as Investors Calmed by Trade Talks

MT Newswires Live
·
09 May

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating

MT Newswires Live
·
09 May

Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib

Dow Jones
·
09 May

US Equity Futures Higher as Trump Considers 80% China Tariffs

MT Newswires Live
·
09 May

Mizuho Securities Reaffirms Their Buy Rating on Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
09 May